Skip to main content

Table 2 Inverse-variance weighted two-sample Mendelian randomization estimates for antihypertensive drug effects and systolic blood pressure reduction through any mechanism (scaled to 10 mmHg) on the set of outcomes

From: Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study

Exposure/drug target Outcome ORa LCI 95% UCI 95% P-value
Beta-blocker mediated 10 mmHg SBP reduction (# SNPs = 2) Pre-eclampsia or eclampsia 0.27 0.06 1.19 0.08
Gestational diabetes 2.01 0.91 4.42 0.08
Birthweighta  − 0.27  − 0.39  − 0.15 1.90 × 10−05
Calcium channel blocker mediated 10 mmHg SBP reduction (# SNPs = 23) Pre-eclampsia or eclampsia 0.62 0.43 0.89 9.33 × 10−3
Gestational diabetes 1.05 0.76 1.45 0.76
Birthweighta 0.02  − 0.04 0.07 0.54
Systolic blood pressure, any mechanism (10 mmHg reduction, # SNPs = 1336–1346) Pre-eclampsia or eclampsia 0.57 0.53 0.60 1.11 × 10−84
Gestational diabetes 0.94 0.90 0.99 0.01
Birthweighta 0.10 0.09 0.11 9.54 × 10−80
  1. Abbreviations: OR Odds ratio, LCI Lower bound for 95% confidence interval, UCI Upper bound for 95% confidence interval
  2. abeta coefficient reported for birthweight